Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 114 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015', provides an overview of the Bipolar Disorder (Manic Depression)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bipolar Disorder (Manic Depression)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Bipolar Disorder (Manic Depression) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Bipolar Disorder (Manic Depression) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bipolar Disorder (Manic Depression) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bipolar Disorder (Manic Depression)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Bipolar Disorder (Manic Depression) Overview 10
Therapeutics Development 11
Pipeline Products for Bipolar Disorder (Manic Depression) - Overview 11
Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis 12
Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies 13
Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes 15
Bipolar Disorder (Manic Depression) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Bipolar Disorder (Manic Depression) - Products under Development by Companies 19
Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes 21
Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development 22
Aequus Pharmaceuticals Inc. 22
ANP Technologies, Inc. 23
AstraZeneca Plc 24
Convergence Pharmaceuticals Ltd. 25
D-Pharm Ltd. 26
Delpor, Inc. 27
Intas Pharmaceuticals Ltd. 28
Intra-Cellular Therapies, Inc. 29
Johnson & Johnson 30
KemPharm, Inc. 31
Neurocrine Biosciences, Inc. 32
Omeros Corporation 33
Otsuka Holdings Co., Ltd. 34
Pfizer Inc. 35
Reviva Pharmaceuticals Inc. 36
SK Biopharmaceuticals Co., Ltd. 37
Sumitomo Dainippon Pharma Co., Ltd. 38
Teva Pharmaceutical Industries Limited 39
Zogenix, Inc. 40
Zysis Limited 41
Bipolar Disorder (Manic Depression) - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
ANP-010 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
aripiprazole - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
aripiprazole CR - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
aripiprazole ER - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CNV-1061436 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
DP-VPA - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Drug for Bipolar Disorder - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Drug for Cancer and Neurodegenerative Disease - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ebselen - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Endoxifen - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ITI-007 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
JNJ-18038683 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
KP-303 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
lurasidone hydrochloride - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
NP-202 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
paliperidone palmitate - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
PGW-5 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
quetiapine fumarate ER - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
risperidone - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
risperidone - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
RP-5063 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
SKL-PSY - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecule for Bipolar Disorder - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecule to Inhibit VMAT-2 for Schizophrenia, Bipolar Disorder and Movement Disorders - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecule to Target GPR50 for CNS and Metabolic Disorders - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Synthetic Peptides to Inhibit IMPase for Bipolar Disorder - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
YKP-3089 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
ziprasidone mesylate - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Bipolar Disorder (Manic Depression) - Recent Pipeline Updates 88
Bipolar Disorder (Manic Depression) - Dormant Projects 104
Bipolar Disorder (Manic Depression) - Discontinued Products 106
Bipolar Disorder (Manic Depression) - Product Development Milestones 107
Featured News & Press Releases 107
Nov 16, 2015: Aequus Receives Approval from Health Canada to Initiate Phase 1 Clinical Trial of Aripiprazole Transdermal Patch 107
Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole 107
Jul 22, 2015: Intra-Cellular Therapies Announces Phase 3 Clinical Development Program for the Treatment of Depressive Episodes Associated With Bipolar Disorder 108
May 28, 2015: Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole 108
Mar 30, 2015: Sunovion Pharmaceuticals Europe to Present New Data on LATUDA (lurasidone) at the 23rd European Congress of Psychiatry 109
Jan 14, 2015: Sunovion Pharmaceuticals Files Patent Infringement Lawsuits Regarding Latuda 110
Jan 13, 2015: Germany's Federal Court Invalidates AstraZeneca's Patent on Seroquel XR 111
Jul 25, 2014: Otsuka announces 2014 second quarter U.S. net sales figures of ABILIFY 111
Apr 30, 2014: Otsuka announces 2014 first quarter U.S. net sales figures of ABILIFY 111
Apr 03, 2014: Dainippon Sumitomo Pharma Announces Health Canada Approval of LATUDA (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Patients with Bipolar Depression 111
Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 113
Disclaimer 114

List of Tables

Number of Products under Development for Bipolar Disorder (Manic Depression), H2 2015 11
Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Late Stage Development, H2 2015 16
Comparative Analysis by Clinical Stage Development, H2 2015 17
Comparative Analysis by Early Stage Development, H2 2015 18
Products under Development by Companies, H2 2015 19
Products under Development by Companies, H2 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2015 21
Bipolar Disorder (Manic Depression) - Pipeline by Aequus Pharmaceuticals Inc., H2 2015 22
Bipolar Disorder (Manic Depression) - Pipeline by ANP Technologies, Inc., H2 2015 23
Bipolar Disorder (Manic Depression) - Pipeline by AstraZeneca Plc, H2 2015 24
Bipolar Disorder (Manic Depression) - Pipeline by Convergence Pharmaceuticals Ltd., H2 2015 25
Bipolar Disorder (Manic Depression) - Pipeline by D-Pharm Ltd., H2 2015 26
Bipolar Disorder (Manic Depression) - Pipeline by Delpor, Inc., H2 2015 27
Bipolar Disorder (Manic Depression) - Pipeline by Intas Pharmaceuticals Ltd., H2 2015 28
Bipolar Disorder (Manic Depression) - Pipeline by Intra-Cellular Therapies, Inc., H2 2015 29
Bipolar Disorder (Manic Depression) - Pipeline by Johnson & Johnson, H2 2015 30
Bipolar Disorder (Manic Depression) - Pipeline by KemPharm, Inc., H2 2015 31
Bipolar Disorder (Manic Depression) - Pipeline by Neurocrine Biosciences, Inc., H2 2015 32
Bipolar Disorder (Manic Depression) - Pipeline by Omeros Corporation, H2 2015 33
Bipolar Disorder (Manic Depression) - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 34
Bipolar Disorder (Manic Depression) - Pipeline by Pfizer Inc., H2 2015 35
Bipolar Disorder (Manic Depression) - Pipeline by Reviva Pharmaceuticals Inc., H2 2015 36
Bipolar Disorder (Manic Depression) - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015 37
Bipolar Disorder (Manic Depression) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 38
Bipolar Disorder (Manic Depression) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 39
Bipolar Disorder (Manic Depression) - Pipeline by Zogenix, Inc., H2 2015 40
Bipolar Disorder (Manic Depression) - Pipeline by Zysis Limited, H2 2015 41
Assessment by Monotherapy Products, H2 2015 42
Number of Products by Stage and Target, H2 2015 44
Number of Products by Stage and Mechanism of Action, H2 2015 46
Number of Products by Stage and Route of Administration, H2 2015 48
Number of Products by Stage and Molecule Type, H2 2015 50
Bipolar Disorder (Manic Depression) Therapeutics - Recent Pipeline Updates, H2 2015 88
Bipolar Disorder (Manic Depression) - Dormant Projects, H2 2015 104
Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..1), H2 2015 105
Bipolar Disorder (Manic Depression) - Discontinued Products, H2 2015 106